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Abstract: We demonstrate feasibility of endoscopic imaging of Cerenkov 
light originated when charged nuclear particles, emitted from radionuclides, 
travel through a biological tissue of living subjects at superluminal velocity. 
The endoscopy imaging system consists of conventional optical fiber 
bundle/ clinical endoscopes, an optical imaging lens system, and a sensitive 
low-noise charge coupled device (CCD) camera. Our systematic studies 
using phantom samples show that Cerenkov light from as low as 1 µCi of 
radioactivity emitted from 
18F-Fluorodeoxyglucose (FDG) can be coupled 
and transmitted through conventional optical fibers and endoscopes. In vivo 
imaging experiments with tumor bearing mice, intravenously administered 
with 
18F-FDG, further demonstrated that Cerenkov luminescence endoscopy 
is a promising new tool in the field of endoscopic molecular imaging. 
© 2012 Optical Society of America 
OCIS codes: (170.2150) Endoscopic imaging; (170.0110) Imaging systems; (170.4580) Optical 
diagnostics for medicine. 
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1. Introduction 
In recent years, molecular imaging has increasingly evolved as an integral imaging modality 
in the diagnosis, surveillance, and treatment monitoring of cancer, as well as neurological and 
cardiovascular diseases [1–3]. In contrast to traditional diagnostic imaging modalities such as 
computed tomography (CT) and ultrasound, which provide predominantly anatomical 
information, molecular imaging  offers insights into the underlying biochemistry with 
molecular specificity. Optical imaging, magnetic resonance imaging (MRI), and positron 
emission tomography (PET) are mainly used for non-invasive molecular imaging. While MRI 
has limited sensitivity (contrast agent concentration: 10
−3 to 10
−5 mol/L), both optical imaging 
and PET provide high sensitivity (radioisotope concentration: 10
−11 to 10
−12 mol/L). While 
optical imaging offers rapid image acquisition, low cost, and the absence of ionizing radiation, 
it is limited by depth of penetration due to the strong attenuation of light by biological tissue. 
Optical endoscopes and laparoscopes deliver light directly to the internal organs through 
natural or surgical orifices. In conventional white light endoscopy, diffusely reflected light 
from the tissue surface is imaged to visualize lesions or structural changes. Several new 
endoscopic technologies exploit light properties such as optical coherence and fluorescence 
[4,5]. For example, fluorescence emitted from endogenous molecules [e.g., aromatic amino 
acids, NADH (nicotinamide adenine dinucleotide) and FAD (flavin adenine dinucleotide)] 
and exogenous fluorescent-labeled probes have been used to determine the biochemical and 
molecular changes in diseased tissues [6,7]. However, optical imaging has been limited by 
paucity of available contrast agents for clinical use, with only three approved by the US Food 
and Drug Administration (FDA): indocyanine green (ICG), methylene blue, and fluorescein. 
These non-specific agents are used to improve tissue contrast and highlight the vasculature. 
For targeted imaging, it still remains a challenge to translate optical molecular contrast agents 
from bench to the clinics, primarily due to concerns for toxicity and immunogenicity. 
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emission computed tomography (SPECT). A relative disadvantage of Cerenkov based 
detection is the need for radioactive tracers that produce ionizing radiation. However the 
tracers are injected at relatively low mass amounts following the safety limits for human 
radiation exposure. The PET probes target intracellular, cell surface, or extracellular matrix 
molecules that are over-expressed in different diseases. For example, 
18F-FDG is used in 
conjunction with PET to assess glucose metabolism in the heart, lungs, the brain and several 
cancer, including lung, breast, colorectal, melanoma, Hodgkin's and non-Hodgkin's lymphoma 
[1,8,9]. It has also been approved for use in diagnosing Alzheimer's disease. Similarly, several 
18F labeled metabolic tracers (e.g., 
18F-Choline) and non-metabolic tracers such as 
18F labeled 
Arginine-Glycine-Asparatic  acid  (RGD)  peptide  that  targets  integrin  receptor  αvβ3, 
18F-
Fluoroazomycin Arabinoside (FAZA) and 
18F-Fluoromisonidazole (FMISO) (tracers that 
selectively accumulate in hypoxic cells), anti-
18F-fluorocyclobutyl-1-carboxylic acid 
[FACBC] (an amino acid analogue) are in pilot clinical trials [10–16]. A dedicated PET-CT 
scanner is used to precisely combine the spatial distribution of metabolic or biochemical 
activity obtained from these PET probes with anatomical information obtained by CT for non-
invasive molecular imaging. The current limitations of PET, however, include limited spatial 
resolution (several mm), relatively high cost, the time consuming nature, and its limited use in 
endoscopy mode. 
New advancements in optical molecular imaging are moving beyond conventional 
fluorescence imaging. In the last couple of years, Cerenkov luminescence imaging (CLI) has 
emerged as an active field of research in biomedical community [17–22]. CLI combines the 
PET probes approved for nuclear medicine applications with optical imaging. Cerenkov light 
is emitted when charged nuclear particles, such as β
+ (positron) or β
− (nuclear electron) from 
radionuclides, travel at superluminal velocity in dielectric medium including biological tissue 
or water. CLI can be performed with positron and electron emitters, unlike SPECT and PET 
that depends on gamma (γ) rays and positrons, respectively. Cerenkov light is continuous and 
occurs mainly in the visible (more intense in the blue) region of the electromagnetic spectrum 
in the wavelength range of 250–1000 nm. This enables in vivo optical imaging using PET 
probes administered intravenously and commercially available optical imaging systems with 
cooled CCD cameras (e.g., IVIS 200 Spectrum, Caliper Life Sciences). We recently 
demonstrated the feasibility of intraoperative imaging of Cerenkov luminescence for 
identifying tumors in mice models using a custom made fiber optic system [23]. Similar to 
conventional optical imaging, however, imaging of internal organs using CLI is challenging 
and limited by the depth of penetration from strong scattering of Cerenkov light as it 
propagates through biological tissue. Detection of Cerenkov light through conventional 
endoscopes may expand potential applications of CLI to common gastrointestinal and urinary 
tract cancers (e.g. esophageal and bladder) that are primarily managed endoscopically, and 
significantly expand the utility of the PET probes. 
In this work, we investigated whether Cerenkov light can be detected through 
conventional optical fibers/clinical endoscopes with a sensitive CCD camera. We studied the 
limits of detection of Cerenkov light emitted from phantom samples containing different 
concentrations of 
18F-FDG using different optical fibers and endoscopes. We further validated 
the feasibility of detecting Cerenkov light emitted from C6 glioma tumor bearing mice after 
intravenous administration of 
18F-FDG, using an endoscopy imaging system that consists of 
optical fiber coupled to a CCD camera. Since PET probes have the capability to targeting 
cancer cells in different regions of the body, the Cerenkov light emitted from these cells can 
then be detected using conventional endoscopes routinely used in the clinic. Our results 
support additional investigations of CLI as a promising modality for endoscopic molecular 
imaging. 
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2.1. Experimental setup 
The optical endoscopy imaging system is consisted of an endoscope (optical fibers and/or 
optical lenses), a white light source, and a CCD camera that is connected to the computer 
monitor. We demonstrate feasibility of Cerenkov luminescence imaging (CLI) using an IVIS 
Imaging System 200 Series (Caliper Life Sciences) as it consists of a sensitive low noise CCD 
camera (quantum efficiency >85% in 500-700 nm, read noise <5 electrons RMS (root mean 
square), dark current <100 electrons/s/cm
2, minimum detectable radiance <70 
photons/s/sr/cm
2, operating temperature –105 °C, field of view 3.9 × 3.9 cm to 26 × 26 cm 
(3.9, 6.5, 13, 19.5, 26 cm)) that is necessary to visualize weak Cerenkov light emitted from 
trace levels of radioactive molecules. Figure 1 shows the schematic of the IVIS System to 
image phantom samples or animal subjects (denoted by “S”) using different optical 
fibers/endoscopes (OF). The subject “S” was placed outside the field of view (FOV) of the 
imaging system. The input end of the OF was placed close to the subject “S”. The output end 
of the “OF” faced the CCD camera such that the image transmitted by the output end is 
imaged on to the CCD camera using a relay lens system. Identical settings were used for both 
in vitro phantom and living mouse experiments. 
FOV
S OF
CCD
camera
 
Fig. 1. IVIS-200 spectrum imaging system was adapted to image phantom samples/animal 
subjects (denoted by “S”), pre-administered with 
18F-FDG, using different optical 
fibers/endoscopes (OF). The subject “S” is placed outside the rectangular field of view (FOV) 
of the imaging system. The input end of the OF is placed close to the subject “S”. The output 
end of the “OF” is facing the CCD camera such that CCD camera is focused on the output end. 
2.2. Endoscopes and optical fibers 
Various diagnostic instruments used in medical examination fall within the broad definition of 
remote sensing, although the target tissue being analyzed is close to the sensor, which may be 
exterior to the body, placed on the body's surface, or inserted inside the body to examine 
internal organs. Most of these instruments work in active mode by sending either 
electromagnetic (EM) radiation (such as visible and radio frequency (RF) radiation) or 
acoustic waves into the body and then sensing/imaging respective reflected signals. In this 
work we use conventional endoscopes and fiber optic cables/bundles in a passive mode for 
remote sensing/imaging of Cerenkov light emitted from a PET probe, 
18F-FDG. The five 
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Storz), rigid cystoscope (Circom ACMI), fiber optic bundle with a 6 mm active diameter, two 
conventional multimode optical fibers with core diameters of 400 µm and 60µm respectively. 
The specifications of these instruments are listed in Table 1. Please note that 2 mm core 
diameter for the flexible cystoscope represents the diameter of the image guide channel (that 
collects light from the tissue and is imaged by the eye piece) at the distal end of the 
cystoscope and not the total diameter of the cystoscope, which includes illumination light 
guide channel besides other channels for water and air use. 
Table 1. Specifications of optical endoscopes/fibers used in the study 
Instrument  Working Length  Numerical Aperture  Core Diameter  Fiber Material 
Flexible Cystoscope  40 cm  in the range of  
0.1 to 0.22 
2 mm for  
image guide 
not known 
Rigid Cystoscope  30 cm  not known  2 mm for  
image guide 
system of optical  
lenses and prisms;  
no fiber 
6 mm fiber bundle  100 cm  0.22  6 mm  silica 
400 μm fiber cable  100 cm  0.22  400 μm  silica 
60 μm fiber cable  100 cm  0.22  60 μm  silica 
In a conventional optical endoscope the distal tip contains the optics required for 
illuminating and collecting endoscopic images and outlet for the working channel. The 
proximal end of the endoscope contains control levers for flexion (up to 270 degrees) of the 
distal tip and the inlet for working channel. While the distal tip of the endoscope was placed 
close to the tissue under investigation, the proximal end that transmits the image was imaged 
on to the CCD camera using a lens system. The Cerenkov light propagating through the tissue 
was isotropically scattered and only a fraction of this light is collected by the endoscope. High 
optical throughput or etendue is therefore critical for high sensitivity measurement such as 
detecting weak light through optically scattering medium (e.g., biological tissue). The 
maximum angle at which an endoscope can collect the light can be as high as 70 degrees. As 
shown in Fig. 2, the etendue of a typical optical fiber is proportional to the area of the fiber 
core and square of numerical aperture (NA) of the fiber. A high NA allows light to propagate 
down the fiber in rays both close to the axis and at various angles, allowing efficient coupling 
of light into the fiber. Etendue therefore, is a limiting function of system throughput. In the 
next section, we employ several optical endoscopes and conventional optical fibers with 
different etendues to study the limits of detection of Cerenkov light from 
18F-FDG solution in 
vitro. 
 
Fig. 2. Acceptance angle of a typical step index fiber with a fiber core of refractive index n1 
greater than refractive index n2 of cladding. Light ray A outside the acceptance angle escapes 
into the cladding; Light ray B within the acceptance angle is guided through the fiber by total 
internal reflection and can therefore be detected by a CCD. 
2.3. 
18F-FDG protocol/tumor model 
18F-FDG was produced by the Radiochemistry Facility at Stanford University using standard 
procedures. Rat glioma cell line C6 was obtained from American Type Culture Collection 
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Laboratories, Inc (Cambridge, MA) were at 4-6 weeks of age. A CRC-15R PET dose 
calibrator  (Capintec Inc., Ramseb, NJ) was used for all radioactivity measurements. All 
animal studies were carried out in compliance with federal and local institutional rules for the 
conduct of animal experimentation. C6 cells were cultured in DMEM medium supplemented 
with 10% fetal bovine serum (FBS) and 1% pencillin/streptomycin (Invitrogen Life 
Technologies, Carlsbad, CA). The cell line was maintained in a humidified atmosphere of 5% 
CO2 at 37°C, with the medium changed every other day. A 75% confluent monolayer was 
detached with trypsin and dissociated into a single cell suspension for further cell culture. 
Approximately 1 × 10
6 C6 cells suspended in phosphate buffered saline (PBS, 0.1 M, pH = 
7.4, Invitrogen, Carlsbad, CA) were implanted subcutaneously in the left flanks of nude mice. 
Tumors were allowed to grow to a size of 150 to 200 mm
3 over 2-3 weeks, and the tumor 
bearing mice were subjected to in vivo imaging studies. For all in vivo and in vitro studies, 
radioactive PET probes were diluted in PBS. As shown in Fig. 1, animals (denoted by “S”) 
were placed in a light-tight chamber under isoflurane anesthesia. For the 
18F-FDG imaging 
study, the mice were fasted overnight prior to the experiment and kept anesthetized during the 
experiment. For the in vivo imaging study, normal mice or mice bearing C6 glioma tumor 
were injected with 
18F-FDG (34.78-35.89 MBq (940-970 μCi) via tail vein. 
3. Results and Discussion 
Figures 3(a)–(d) show Cerenkov luminescence imaging from a phantom sample (0.2 ml PCR 
tube) containing 0.37 MBq (10 μCi) of 
18F-FDG in 10 μL of PBS using different cystoscopes 
and optical fibers with a one minute exposure time. Specifications of these optical 
endoscopes/fibers are mentioned in the Table 1. These instruments, denoted by “OF” (optical 
fiber) in Fig. 2, were placed in a modified IVIS imaging system such that their distal end is 
kept close (within 1 mm) to the sample “S” to maximize the light coupling efficiency. In Fig. 
3(a), “S” represents the IVIS image of Cerenkov light emitted from the 10 μCi of 
18F-FDG 
phantom sample. This image represents amount of light that is coupled into the distal end 
(marked by arrow) of all instruments in Figs. 3(a)–(d). The Cerenkov light rays that fall within 
the acceptance angle of the respective instruments are guided by total internal reflection and 
exit at the proximal end. The proximal ends of these instruments that transmit the Cerenkov 
signal were imaged, as shown in the right panel of Figs. 3(a)–(d), by the CCD camera of the 
IVIS imaging system using a system of relay lenses. These images show that 
etendue/throughput of a 6 mm fiber optic bundle is relatively high compared to other 
instruments used in the study. We further investigated limits of detection of Cerenkov 
luminescence emitted from phantom samples (0.2 ml PCR tubes) containing decreasing 
concentrations of 
18F-FDG using above mentioned cystoscopes and fibers. These results, 
plotted in Fig. 4, show that Cerenkov light from as low as 1 µCi of 
18F-FDG can be reliably 
detected using the above instruments. The total Cerenkov light transmitted, within one minute 
integration time, from the entire active area of each fiber/endoscope is used for the limit 
calculation. While the total diameters of the cystoscopes at the distal end are about 4 to 5 mm, 
the diameter of image guides that transmit light to the eyepiece (as shown in the right panel of 
Figs. 3(a) and (b)) are only about 2 mm. The fraction of Cerenkov light that is coupled to the 
illumination guides (that are about 2 mm in diameter) at the distal end and transmitted to the 
proximal end of the illumination guides (marked as dashed rectangular boxes in (a) and (b)) is 
not taken into consideration for the limit calculation. At any given concentration the signal 
detected by a 6 mm fiber optic bundle is higher compared to the other instruments. All clinical 
endoscopes have a 6 mm accessory port to deliver special instruments/catheters into the body. 
This allows a 6 mm fiber optic bundle to pass through the port and reach the organ of interest 
in the body. 
For 
18F-FDG PET studies on a primary bladder tumor in humans, a standard uptake value 
(SUV) of ~4.5 is reported [24]. Thus about 1 μCi of the probe is expected in 0.1 cc bladder 
cancer at 2 hours after intravenous injection of 10 mCi 
18F-FDG (no decay correction). 
Although a 6 mm fiber optic bundle used in this study met this requirement, a more sensitive  
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Fig. 3. Phantom sample (0.2 ml PCR tube) containing about 10 μCi of 
18F-FDG in 10 μL of 
PBS was imaged using different optical fibers and endoscopes with a one minute exposure 
time. Arrows in all figures indicate the distal end of the respective instruments which are within 
1 mm distance from the phantom sample. The dashed rectangular boxes in (a) and (b) show the 
white light illumination channels of respective cystoscopes through which also we observed (in 
absence of the white illumination) the Cerenkov light. 
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Fig. 4. Detection limits of various optical endoscopes and fibers. Luminescence detected by 
different fibers as a function of concentration of 
18F-FDG with one minute exposure time 
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aperture, larger diameter optic bundle, high packing fraction, low reflection and transmission 
losses) can likely further improve the sensitivity and signal to noise ratio of the imaging 
system. Improved sensitivity can also be achieved using a radionuclide with a high mean 
energy beta particle such as 
90Y, that produces approximately 15 times stronger signal than 
18F-FDG used in the study [18]. 
From Figs. 3 and 4 we found that that 6 mm fiber bundle performed better compared to 
other fibers/endoscopes and is a good candidate for our in vivo animal studies. We first 
quantified the transmission efficiency of the 6 mm fiber optic bundle using two collimated 
laser sources, a 633 nm He-Ne laser and a 532 nm laser diode. We found that 6 mm fiber 
bundle has about 50% transmission efficiency at both the wavelengths. 
We then studied spectral characteristics and transmission efficiency of Cerenkov light, 
emitted from 10µCi of 
18F-FDG in 10µL solution, transmitted through the 6 mm fiber optic 
bundle. As shown in the experimental setup in Fig. 1, a 0.2 ml PCR tube containing 10 μCi of 
18F-FDG in 10 μL of PBS is placed close (within 1 mm) to the distal end of the fiber to 
maximize the light coupling efficiency into the fiber. 
Our study included blocking the coupling of Cerenkov light into the fiber using a thick 
black paper (to record gamma scintillation), unblocking by removing the black paper (to 
record all the luminescence), and also removing the radioactive samples (to measure the 
background). Three images (total Cerenkov luminescence, background luminescence by 
inserting black paper, background noise with no radioactivity) were captured at each 
wavelength using a 20 nm narrow band pass filter, the IVIS imaging system. At the end of the 
experiment three images were also captured in open filter position of the IVIS imaging 
system. In Fig. 5, the decay and background corrected Cerenkov luminescence was plotted 
against wavelength range from 500 nm to 840 nm with a 20 nm step size. 
Based on these studies we quantified the contribution of gamma scintillation, when high 
energy gamma radiation from 
18F-FDG radioactive solution is irradiating the 6 mm optical 
fiber optic bundle, to the total Cerenkov light detected. Our experimental results show that the 
contribution of gamma scintillation when the radioactive sample is within the field of view of 
the imaging system and when not in the field of view of the imaging system is about 9.5% and 
3% respectively. In addition our results show that background (gamma scintillation) corrected  
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Fig. 5. Spectral characteristics of Cerenkov luminescence, emitted from 10µCi of 
18F-FDG in 
10µL solution, transmitted through the 6mm fiber optic bundle and detected using a narrow 
band pass filter (20 nm) in the IVIS imaging system with one minute exposure time (decay 
corrected and also background corrected). 
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is about 50% in the visible region and about 40% in the near infrared region (720 nm to 
840nm). The loss in the transmission efficiency can be attributed to several factors such as, 
reflection and transmission losses, not being able to transmit light in the spaces between the 
fibers, low packing fraction, and low numerical aperture. 
We further validated our imaging system using in vivo small animal experiments. As 
shown in Fig. 2, the sample S that is outside the FOV of the imaging system was replaced 
with a mouse under anesthesia while using a OF that was a 6 mm fiber optic bundle. Mice (n 
= 4) bearing subcutaneous C6 glioma were administered with 34.78-35.89 MBq (940-970 
μCi) 
18F-FDG via tail vein injection and imaged 90 minutes post-injection using the fiber 
bundle. The distal end of the fiber bundle is placed (outside the body) close to several tissues 
of interest. The proximal end that transmits Cerenkov light originated from the respective 
tissue (due to the 
18F-FDG uptake) was imaged by the CCD camera of the imaging system. 
Figure 6 shows Cerenkov luminescence imaging results from a 6 mm fiber bundle overlaid on 
a bright-field image of the mouse for anatomical reference. Relatively high signals from the 
subcutaneous tumor and brain indicate high tracer uptake in these organs. 
 
Fig. 6. In vivo animal imaging using 6 mm fiber optic bundle with one minute exposure time. 
Animals (n = 4) bearing sub-cutaneous C6 glioma tumor is intravenously administered with 
34.78-35.89 MBq (940-970 μCi) of 
18F-FDG then sacrificed at one hour post injection for 
imaging. 
To further characterize the distribution of 
18F-FDG, tumors and other organs were 
removed from the sacrificed mice (n = 4) and subjected to imaging using the 6 mm fiber 
bundle as mentioned above. Inset figure on top right corner of each organ in Fig. 7(a) 
represents average Cerenkov radiance detected by the fiber bundle. Figure 7(b) represents 
biodistribution of 
18F-FDG in various tissues at one hour post injection in mice as measured 
using Cerenkov luminescence. Respective tissue Cerenkov luminescence was measured by a 6 
mm fiber optic bundle (n = 4 for all organs). Bars represent the average tissue uptake 
plus/minus standard deviation (expressed as % injected dose/g of tissue). High signal was 
mainly observed from the tumor, heart, brain, and kidney tissue samples. 
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Fig. 7. (a) Ex vivo  Cerenkov luminescence imaging, with one minute exposure  time, of 
different organs of an animal bearing C6 glioma tumor dissected after one hour post 
intravenous administration of 900 μCi 
18F-FDG. Inset figure on top right corner of each organ 
represents average Cerenkov radiance detected by a 6 mm fiber optic bundle. (b) 
Biodistribution of 
18F-FDG in various tissues at one hour post injection in mice as measured 
using Cerenkov luminescence. Respective tissue Cerenkov luminescence was measured by a 6 
mm fiber optic bundle (n = 4 for all organs). Bars represent the average tissue uptake 
plus/minus standard deviation (expressed as % injected dose/g of tissue). 
Since 
18F-FDG can be easily produced and widely used in the clinic, we chose to work 
with this radioactive tracer in our study despite relatively low levels of Cerenkov light from 
this tracer compared to other tracers reported in the literature [18]. The amount of 
radioactivity (34.78-35.89 MBq (940-970 μCi) of 
18F-FDG) injected into the animals in our 
study can be reduced by improving the sensitivity of the fiber detection technique and also 
choosing a radioactive tracer that emits higher Cerenkov light. The 6 mm fiber bundle that we 
used has only 50% transmission efficiency due to low packing fraction, high attenuation 
(reflection and transmission losses), and low numerical aperture (0.22) of the fiber. For 
example, the new high power fiber light guides made out of fused silica and high numerical 
aperture (0.37 NA to 0.55 NA) exhibit steady transmission at 95% of original input to the 
fibers. They eliminate inter-fiber spaces—without the need for epoxy and its inherent limiting 
properties. These developments and several technological revolutions taking place in fiber 
optics [25] and CCD/CMOS sensors can further improve the sensitivity of the technique. This 
may help to translate CLI into human studies for applications in endoscopic, laparoscopic, and 
robotic-assisted cancer surgery. For example, standard laparoscopic trocars can accommodate 
instruments up to 12 mm in diameter, through which a 12 mm fiber optic bundle can be 
inserted, which can perform better than 6 mm fiber optic bundle used in this study. Further 
coherent image guide fiber bundles can be used to improve resolution and delineate the region 
emitting Cerenkov light from the surrounding tissue. 
4. Conclusion 
We demonstrate that Cerenkov light can be coupled and transmitted through different clinical 
endoscopes and conventional optical fibers for potential applications during clinical 
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increase in the etendue of the endoscope/optical fiber. Cerenkov light from as low as 1 μCi of 
radioactivity emitted from 
18F-FDG was reliably detected using a 6 mm fiber optic bundle. 
The feasibility of Cerenkov luminescence imaging using a 6 mm fiber was demonstrated by 
non-invasive in vivo imaging of mice bearing C6 glioma with intravenous 
18F-FDG. Cerenkov 
light emitted from the tumor and other organs of the mouse were detected one hour post-
injection, with higher tumor uptake of 
18F-FDG compared to the surrounding tissue. We 
further validated our in-vivo results with respective ex-vivo imaging of different organs. Our 
promising results support future investigations of endoscopic molecular imaging based on 
Cerenkov luminescence. 
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